API | gepotidacin

gepotidacin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Gepotidacin (INN) is an experimental antibiotic that acts as a topoisomerase type II inhibitor. It is being studied for the treatment of uncomplicated urinary tract infection and infection with Neisseria gonorrhoeae (gonorrhea), including multidrug resistant strains. ^Wikipedia

Chemistry

SMILES: O=c1ccc2ncc(=O)n3c2n1C[C@H]3CN1CCC(NCc2cc3c(cn2)OCCC3)CC1
InChIKey: PZFAZQUREQIODZ-LJQANCHMSA-N
Mol. Mass: 448.53
ALogP: 1.09 Partition coefficient
ChEMBL Molecule:
gepotidacin

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA gyrase subunit A (Escherichia coli K-12) ^UniProt
- DNA gyrase subunit B (Escherichia coli K-12) ^UniProt
- DNA topoisomerase type IB small subunit (Leishmania major) ^UniProt
- DNA topoisomerase 4 subunit A (Escherichia coli K-12) ^UniProt
- DNA topoisomerase 4 subunit B (Escherichia coli K-12) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

gepotidacin | gsk2140944

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Bacterial Infections (Phase 2)

Gonorrhea (Phase 3)

Healthy Volunteers (Phase 1)

Respiratory Tract Infections (Phase 1)

Urinary Tract Infections (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 21
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue